Results 81 to 90 of about 37,793 (186)
Remdesivir—Bringing Hope for COVID-19 Treatment
, 2020 At the beginning of 2020, the world was swept with a wave of a new coronavirus disease, named COVID-19 by the World Health Organization (WHO 2). The causative agent of this infection is the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 ...
Naser F. Al-Tannak +2 more
core +1 more source
Remdesivir in a pregnant patient with COVID-19 pneumonia
, 2021 Remdesivir is an antiviral drug currently being studied as a potential treatment of pneumonia caused by infection with SARS-CoV-2. The Adaptive Covid-19 Treatment Trial (ACTT-1) by NIH and the SIMPLE study by Gilead Sciences are two major trials that ...
Ranadheer Dande +5 more
core +1 more source
Chiral (Stereoselective) Drugs, Asymmetric Synthesis, and Racemic Resolution Methods
Chirality, Volume 38, Issue 7, July 2026.Chirality is crucial in drug development since both biological targets in the organism and the majority of pharmaceutical compounds are chiral. The synthesis and resolution of chiral compounds are critical steps while developing chiral drugs. Asymmetric synthesis and racemic resolution are the two most common methods for obtaining enantiopure drugs ...
Burcu Karayavuz +1 more
wiley +1 more source
, 2020 Ante la gran cantidad de información circulante respecto a los medicamentos para el tratamiento de COVID-19 y considerando que es necesario ser objetivos respecto a la información fiable y científica disponible referente al medicamento (ifa) REMDESIVIR ...
Manassero, Carlos
core
CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 7, July 2026.PBPK/PD modeling and clinical retrospective validation of intravenous polymyxin B in critically ill patients with pulmonary infection. ABSTRACT Intravenous polymyxin B (PMB) is widely used for treating drug‐resistant gram‐negative pneumonia, though its efficacy in pulmonary infections is considered limited.
Shengnan Zhang +9 more
wiley +1 more source
COVID‐19 Mortality in Swedish Intensive Care Units: A Multicenter Survival Analysis
Acta Anaesthesiologica Scandinavica, Volume 70, Issue 6, July 2026.ABSTRACT Background Mortality among critically ill COVID‐19 patients has varied globally. In Sweden, geographic differences in mortality have also been observed. The current study aimed to determine whether mortality differences persist after adjusting for differences in case‐mix, and to identify potential independent factors contributing to regional ...
Gustaf Forsberg +10 more
wiley +1 more source
DataSheet3_Protective Effect of Remdesivir Against Pulmonary Fibrosis in Mice.docx
, 2021 Pulmonary fibrosis is a known sequela of severe or persistent lung damage. Existing clinical, imaging and autopsy studies have shown that the lungs exhibit a pathological pulmonary fibrosis phenotype after infection with coronaviruses, including severe ...
Jingjing Liang (413293) +10 more
core +1 more source
BMC Chemistry, 2023 Favipiravir and remdesivir have been included in the COVID-19 treatment guidelines panel of several countries. The main objective of the current work is to develop the first validated green spectrophotometric methods for the determination of favipiravir ...
Afnan S. Batubara +4 more
doaj +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1514-1522, April 2025.
Takamasa Iwai +4 more
wiley +1 more source
Influenza and Other Respiratory Viruses, Volume 20, Issue 7, July 2026.ABSTRACT Background The 8th International Society for Respiratory Viruses (ISRV) Antiviral Group Conference, held jointly with the 3rd International Meeting on Respiratory Pathogens in Singapore (17–20 September 2025), examined evolving approaches to prevention and management of respiratory infections.
Narmadha Morvil +5 more
wiley +1 more source